World-leading pathologist Associate Professor Michael Tetzlaff visits MIA
20 December 2018
Melanoma Institute Australia (MIA) is proud to have one of the world’s leading pathologists, Associate Professor Michael Tetzlaff, with us for this past week.
A/Prof Tetzlaff hails from the Department of Pathology and Translational and Molecular Pathology at the MD Anderson Cancer Centre at The University of Texas.
Spending his time with fellow pathologist Professor Richard Scolyer, MIA’s Co-Medical Director, and his team at Royal Prince Alfred Hospital, A/Prof Tetzlaff is sharing his pathological expertise in primary mucosal melanoma and merkel cell carcinoma, and assisting in the assessment of pathological samples from patients undergoing neoadjuvant, targeted therapy.
Among over 100 published peer-reviewed articles, A/Prof Tetzlaff is also lead author on a paper recently published by the International Neoadjuvant Melanoma Consortium that aims to standardise the pathologic evaluation of resected melanoma metastases following neoadjuvant-targeted or immune-checkpoint therapy.
It is an honour to have Associate Professor Tetzlaff as an international collaborator, and we are delighted to be hosting him on his first ever trip to Australia.
The World Congress on Cancers of the Skin 2018 has featured many minds from MIA sharing their expertise and wealth of knowledge with over 1000 attendees from around the world.
Melanoma Institute Australia is delighted to announce the appointment of Matthew Browne as Chief Executive Officer (CEO).
It was a full house this week at Melanoma Institute Australia thanks to our ‘Melanoma in Practice: Nurse Conference’.
A new study from The University of Sydney shows that sunscreen reduces melanoma risk by 40 per cent when used from a young age.
Melanoma Institute Australia (MIA) has launched a free e-learning portal to educate healthcare professionals about the latest advances in melanoma diagnosis and treatment.
When David lost his life last year, he was 33, with three daughters under six.
Clinical trials are just that – trials in a clinical setting to evaluate the effectiveness or otherwise of individual and combination treatments.
Melanoma Institute Australia scooped the award pool at the Annual Scientific Meeting of the International Academy of Pathology.
Melanoma patients across Australia will benefit from the release of updated clinical care guidelines.
An American study has discovered a link between early detection and marital status in melanoma diagnosis.
An international course on melanoma pathology in Paris, France co-directed by Professor Richard Scolyer took place over the weekend.
Professor Richard Scolyer highlights the difficulties of diagnosis following the Australian Story feature program on Emma Betts.
Cancer Australia releases 'stage at diagnosis' data for top five incidence cancers – including melanoma
For the first time in Australia, national data has been released on cancer stage at diagnosis. This data explores the top five incidence cancers – female breast cancer, colorectal, lung, prostate cancers and melanoma.
'Dear Emma' - a tribute to the life and times of a young woman determined to raise awareness about melanoma.
Carole Renouf, CEO for MIA thanks Toyota for helping fuel ongoing melanoma research.
Fraser Dykes tackled the Kokoda Trail on an eight day trek in memory of his friend Mark 'Bod' Boddison.
Harvard’s Clinical Professor Martin Mihm and MIA’s Conjoint Medical Director Professor Richard Scoyler delivered a series of lectures on melanoma pathology in Vancouver, British Colombia this week at the world’s biggest annual pathology meeting.
A round of applause for a well deserved win.
A message from our CEO, Carole Renouf